|Bid||30.52 x 1000|
|Ask||31.01 x 1000|
|Day's range||30.03 - 31.34|
|52-week range||11.19 - 31.80|
|Beta (5Y monthly)||0.78|
|PE ratio (TTM)||N/A|
|Earnings date||03 Nov 2021 - 08 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||35.29|
Merus N.V. (MRUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
This biotech's second experimental cancer drug to begin clinical trials produced some encouraging results.
Tumor shrinkage and partial responses observed in patients with advanced head and neck squamous cell carcinoma (HNSCC) treated with MCLA-158In preclinical studies, Zeno observed to block cell growth 100 fold more potently than anti-HER3 antibody alone UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Bicl